Skip to main content
SpringerLink
Log in

Allogeneic stem cell transplantation in patients with de novo diffuse large B-cell lymphoma who experienced relapse or progression after autologous stem cell transplantation: a Korea–Japan collaborative study

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Patients with diffuse large B-cell lymphoma (DLBCL) who failed autologous stem cell transplantation (auto-SCT) generally have a poor prognosis. Allogeneic stem cell transplantation (allo-SCT) has been implemented to overcome this problem. We report clinical outcomes of allo-SCT in patients with de novo DLBCL who failed auto-SCT from four hospitals in Korea and Japan. Thirty patients were included. The median age was 39 (range, 22–59) years. The 5-year event-free survival (EFS) and overall survival (OS) after allo-SCT were 37.9 % and 42.6 %, respectively. There was only a single event beyond 12 months in the Kaplan-Meier curve of EFS. Non-relapse mortality (NRM) was reported in five patients (16.7 %). In the multivariate analysis, the risk factors for EFS were prior chemotherapy lines ≥ 5 (p = 0.010) and chemo-resistant disease (p = 0.007). The risk factors for OS were chemo-resistant disease (p = 0.024) and Eastern Cooperative Oncology Group performance status 2 (p = 0.005). NRM was associated with prior chemotherapy lines ≥ 5 (p = 0.042), chemo-resistant disease (p = 0.009), and poor performance status (p < 0.001). In conclusion, allo-SCT showed considerable efficacy in patients with DLBCL whose disease was relapsed or progressed after auto-SCT. Our data suggest that allo-SCT could be a viable treatment option if patients have fewer lines of prior chemotherapy, chemo-sensitive disease, and/or good PS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, Sonneveld P, Gisselbrecht C, Cahn JY, Harousseau JL et al (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med 333(23):1540–1545

    Article  CAS  PubMed  Google Scholar 

  2. Stiff PJ, Unger JM, Cook JR, Constine LS, Couban S, Stewart DA, Shea TC, Porcu P, Winter JN, Kahl BS, Miller TP, Tubbs RR, Marcellus D, Friedberg JW, Barton KP, Mills GM, LeBlanc M, Rimsza LM, Forman SJ, Fisher RI (2013) Autologous transplantation as consolidation for aggressive non-Hodgkin’s lymphoma. N Engl J Med 369(18):1681–1690. doi:10.1056/NEJMoa1301077

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  3. Milpied N, Deconinck E, Gaillard F, Delwail V, Foussard C, Berthou C, Gressin R, Lucas V, Colombat P, Harousseau JL (2004) Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 350(13):1287–1295. doi:10.1056/NEJMoa031770

    Article  CAS  PubMed  Google Scholar 

  4. Rodriguez J, Caballero MD, Gutierrez A, Solano C, Arranz R, Lahuerta JJ, Sierra J, Gandarillas M, Perez-Simon JA, Zuazu J, Lopez-Guillermo A, Sureda A, Carreras E, Garcia-Larana J, Marin J, Garcia JC, Fernandez De Sevilla A, Rifon J, Varela R, Jarque I, Albo C, Leon A, SanMiguel J, Conde E (2004) Autologous stem-cell transplantation in diffuse large B-cell non-Hodgkin’s lymphoma not achieving complete response after induction chemotherapy: the GEL/TAMO experience. Ann Oncol 15(10):1504–1509. doi:10.1093/annonc/mdh391

    Article  CAS  PubMed  Google Scholar 

  5. Vose JM, Bierman PJ, Anderson JR, Kessinger A, Pierson J, Nelson J, Frappier B, Schmit-Pokorny K, Weisenburger DD, Armitage JO (1992) Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: clinical course and patient follow-up. Blood 80(8):2142–2148

    CAS  PubMed  Google Scholar 

  6. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, Rimm AA, Ringden O, Rozman C, Speck B et al (1990) Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75(3):555–562

    CAS  PubMed  Google Scholar 

  7. van Kampen RJ, Canals C, Schouten HC, Nagler A, Thomson KJ, Vernant JP, Buzyn A, Boogaerts MA, Luan JJ, Maury S, Milpied NJ, Jouet JP, Ossenkoppele GJ, Sureda A (2011) Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin’s lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry. J Clin Oncol 29(10):1342–1348. doi:10.1200/JCO.2010.30.2596

    Article  PubMed  Google Scholar 

  8. Rigacci L, Puccini B, Dodero A, Iacopino P, Castagna L, Bramanti S, Ciceri F, Fanin R, Rambaldi A, Falda M, Milone G, Guidi S, Martelli MF, Mazza P, Oneto R, Bosi A, Trapianto GI, di Midollo O (2012) Allogeneic hematopoietic stem cell transplantation in patients with diffuse large B cell lymphoma relapsed after autologous stem cell transplantation: a GITMO study. Ann Hematol 91(6):931–939. doi:10.1007/s00277-011-1395-9

    Article  PubMed  Google Scholar 

  9. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M (1971) Report of the committee on Hodgkin’s disease staging classification. Cancer Res 31(11):1860–1861

    CAS  PubMed  Google Scholar 

  10. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP (1999) Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17(4):1244

    CAS  PubMed  Google Scholar 

  11. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25(5):579–586. doi:10.1200/JCO.2006.09.2403

    Article  PubMed  Google Scholar 

  12. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, Thomas ED (1995) 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 15(6):825–828

    CAS  PubMed  Google Scholar 

  13. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE, Hackman R, Tsoi MS, Storb R, Thomas ED (1980) Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 69(2):204–217

    Article  CAS  PubMed  Google Scholar 

  14. de Lima M, van Besien KW, Giralt SA, Khouri IF, Mehra R, Andersson BS, Przepiorka D, Gajewski JL, Korbling M, Champlin RE (1997) Bone marrow transplantation after failure of autologous transplant for non-Hodgkin’s lymphoma. Bone Marrow Transplant 19(2):121–127. doi:10.1038/sj.bmt.1700614

    Article  PubMed  Google Scholar 

  15. Freytes CO, Loberiza FR, Rizzo JD, Bashey A, Bredeson CN, Cairo MS, Gale RP, Horowitz MM, Klumpp TR, Martino R, McCarthy PL, Molina A, Pavlovsky S, Pecora AL, Serna DS, Tsai T, Zhang MJ, Vose JM, Lazarus HM, van Besien K (2004) Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: a report of the International Bone Marrow Transplant Registry. Blood 104(12):3797–3803. doi:10.1182/blood-2004-01-0231

    Article  CAS  PubMed  Google Scholar 

  16. Morris E, Thomson K, Craddock C, Mahendra P, Milligan D, Cook G, Smith GM, Parker A, Schey S, Chopra R, Hatton C, Tighe J, Hunter A, Peggs K, Linch D, Goldstone A, Mackinnon S (2004) Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood 104(13):3865–3871. doi:10.1182/blood-2004-03-1105

    Article  CAS  PubMed  Google Scholar 

  17. Rezvani AR, Norasetthada L, Gooley T, Sorror M, Bouvier ME, Sahebi F, Agura E, Chauncey T, Maziarz RT, Maris M, Shizuru J, Bruno B, Bredeson C, Lange T, Yeager A, Sandmaier BM, Storb RF, Maloney DG (2008) Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience. Br J Haematol 143(3):395–403. doi:10.1111/j.1365-2141.2008.07365.x

    Article  PubMed Central  PubMed  Google Scholar 

  18. Robinson SP, Goldstone AH, Mackinnon S, Carella A, Russell N, de Elvira CR, Taghipour G, Schmitz N, Lymphoma Working Party of the European Group for B, Bone Marrow T (2002) Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 100(13):4310–4316. doi:10.1182/blood-2001-11-0107

    Article  CAS  PubMed  Google Scholar 

  19. Escalon MP, Champlin RE, Saliba RM, Acholonu SA, Hosing C, Fayad L, Giralt S, Ueno NT, Maadani F, Pro B, Donato M, McLaughlin P, Khouri IF (2004) Nonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin’s lymphoma whose disease has failed a prior autologous transplantation. J Clin Oncol 22(12):2419–2423. doi:10.1200/JCO.2004.09.092

    Article  PubMed  Google Scholar 

  20. Peggs KS, Mackinnon S, Linch DC (2005) The role of allogeneic transplantation in non-Hodgkin’s lymphoma. Br J Haematol 128(2):153–168. doi:10.1111/j.1365-2141.2004.05251.x

    Article  PubMed  Google Scholar 

  21. Schmitz N, Dreger P, Glass B, Sureda A (2007) Allogeneic transplantation in lymphoma: current status. Haematologica 92(11):1533–1548. doi:10.3324/haematol.11185

    Article  PubMed  Google Scholar 

  22. Sorror ML, Storer BE, Maloney DG, Sandmaier BM, Martin PJ, Storb R (2008) Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia. Blood 111(1):446–452. doi:10.1182/blood-2007-07-098483

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  23. van Besien KW, de Lima M, Giralt SA, Moore DF Jr, Khouri IF, Rondon G, Mehra R, Andersson BS, Dyer C, Cleary K, Przepiorka D, Gajewski JL, Champlin RE (1997) Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect. Bone Marrow Transplant 19(10):977–982. doi:10.1038/sj.bmt.1700781

    Article  PubMed  Google Scholar 

  24. Bishop MR, Dean RM, Steinberg SM, Odom J, Pavletic SZ, Chow C, Pittaluga S, Sportes C, Hardy NM, Gea-Banacloche J, Kolstad A, Gress RE, Fowler DH (2008) Clinical evidence of a graft-versus-lymphoma effect against relapsed diffuse large B-cell lymphoma after allogeneic hematopoietic stem-cell transplantation. Ann Oncol 19(11):1935–1940. doi:10.1093/annonc/mdn404

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  25. Marks DI, Lush R, Cavenagh J, Milligan DW, Schey S, Parker A, Clark FJ, Hunt L, Yin J, Fuller S, Vandenberghe E, Marsh J, Littlewood T, Smith GM, Culligan D, Hunter A, Chopra R, Davies A, Towlson K, Williams CD (2002) The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation. Blood 100(9):3108–3114. doi:10.1182/blood-2002-02-0506

    Article  CAS  PubMed  Google Scholar 

  26. Mandigers CM, Verdonck LF, Meijerink JP, Dekker AW, Schattenberg AV, Raemaekers JM (2003) Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation. Bone Marrow Transplant 32(12):1159–1163. doi:10.1038/sj.bmt.1704290

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The authors acknowledge the efforts of the Korean Society of Blood and Marrow Transplantation (KSBMT) for coordinating this cooperative study. This work was supported by a grant from the National Research Foundation (NRF) of Korea (No. 2011-0029703), Ministry of Education, Science, and Technology and a grant from the Korean Health Technology R&D Project (PGM21-A111218), Ministry of Health and Welfare, Korea.

Conflict of interest

The authors have declared no conflicts of interest.

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul, 110-744, South Korea

    Ji-Won Kim, Ji-Hyun Kwon, Inho Kim, Sung-Soo Yoon & Seonyang Park

  2. Cancer Research Institute, Seoul National University, Seoul, South Korea

    Ji-Won Kim, Ji-Hyun Kwon, Inho Kim, Sung-Soo Yoon & Seonyang Park

  3. Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan

    Sung-Won Kim, Kohei Tada & Takahiro Fukuda

  4. Department of Internal Medicine, Asan Medical Center, Seoul, South Korea

    Je-Hwan Lee

  5. Department of Hematology–Oncology, Chonnam National University Hwasun Hospital, Gwangju, South Korea

    Je-Jung Lee

  6. Clinical Research Institute, Seoul National University Hospital, Seoul, South Korea

    Ji-Hyun Kwon, Inho Kim, Sung-Soo Yoon & Seonyang Park

  7. Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea

    Soo-Mee Bang & Jong Seok Lee

Authors
  1. Ji-Won Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sung-Won Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kohei Tada
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Takahiro Fukuda
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Je-Hwan Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Je-Jung Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ji-Hyun Kwon
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Soo-Mee Bang
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Inho Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Sung-Soo Yoon
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Jong Seok Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Seonyang Park
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sung-Soo Yoon.

Additional information

Ji-Won Kim and Sung-Won Kim contributed equally to this study.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kim, JW., Kim, SW., Tada, K. et al. Allogeneic stem cell transplantation in patients with de novo diffuse large B-cell lymphoma who experienced relapse or progression after autologous stem cell transplantation: a Korea–Japan collaborative study. Ann Hematol 93, 1345–1351 (2014). https://doi.org/10.1007/s00277-014-2045-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-014-2045-9

Keywords

Search

Navigation